Managers / Q4 2020 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $481M in U.S.-listed holdings across 17 positions for Q4 2020.
Its largest position, SPRO, represents 15.8% of the portfolio.
Compared with Q3 2020, the fund opened 3 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 60.6% · $292M
- ETP · 30.4% · $146M
- Other · 6.0% · $29M
- ADR · 3.0% · $14M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| IBBISHARES TR | NEW | +500.0K | 500.0K | +$76M | $76M |
| AMRYT PHARMA PLC | NEW | +800.0K | 800.0K | +$11M | $11M |
| FDMT4D MOLECULAR THERAPEUTICS IN | NEW | +20.0K | 20.0K | +$829,000 | $829,000 |
| MAGENTA THERAPEUTICS INC | ADDED | +1.31M | 2.27M | +$11M | $18M |
| GALAPAGOS NV | ADDED | +37.5K | 70.0K | +$2M | $7M |
| IWMISHARES TR RUSSELL 2000 | SOLD OUT | −1.70M | 0 | −$255M | $0 |
| PROQR THRAPEUTICS N V | SOLD OUT | −2.28M | 0 | −$11M | $0 |
| AC IMMUNE SA | SOLD OUT | −463.6K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SPROSPERO THERAPEUTICS INChistory → | COM | 15.85% | $76M | 3.93M |
| 2 | BLUEPRINT MEDICINES CORP | COM | 8.86% | $43M | 380.0K |
| 3 | NGM BIOPHARMACEUTICALS INC | COM | 6.33% | $30M | 1.01M |
| 4 | DICERNA PHARMACEUTICALS INC | COM | 6.21% | $30M | 1.36M |
| 5 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 5.84% | $28M | 365.9K |
| 6 | ANABANAPTYSBIO INChistory → | COM | 5.43% | $26M | 1.22M |
| 7 | QUREUNIQURE NVhistory → | SHS | 5.27% | $25M | 702.0K |
| 8 | RGNXREGENXBIO INChistory → | COM | 4.75% | $23M | 503.4K |
| 9 | MAGENTA THERAPEUTICS INC | COM | 3.69% | $18M | 2.27M |
| 10 | AMRYT PHARMA PLC | SPONSORED ADS | 2.35% | $11M | 800.0K |
| 11 | PIERIS PHARMACEUTICALS INC | COM | 1.91% | $9M | 3.68M |
| 12 | GALAPAGOS NV | SPON ADR | 1.44% | $7M | 70.0K |
| 13 | ARGXARGENX SE | SPONSORED ADR | 0.78% | $4M | 12.7K |
| 14 | GMABGENMAB A/S | SPONSORED ADS | 0.76% | $4M | 90.0K |
| 15 | FDMT4D MOLECULAR THERAPEUTICS IN | COM | 0.17% | $829,000 | 20.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.